TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12791117
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose alone (BD) - pethidine 0.3 mg.kg‐1 loading dose and 150 micro g.kg‐1 bolus intravenously
Study: 12791117
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose with background infusion (BD + BI) - pethidine 0.3 mg.kg‐1 loading dose, 75 micro g.kg‐1 bolus, and 15 micro g.kg‐1.h‐1 background infusion
Study: 8968267
Drug: Diaspirin cross‐linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaspirin cross‐linked hemoglobin solution (100 mg/kg)
Study: 8968267
Drug: Diaspirin cross‐linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaspirin cross‐linked hemoglobin solution (25 mg/kg)
Study: 8968267
Drug: Diaspirin cross‐linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaspirin cross‐linked hemoglobin solution (50 mg/kg)
Study: 8968267
Drug: Diaspirin cross‐linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaspirin cross‐linked hemoglobin solution
Study: 29408444
Drug: Control (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (lactated Ringer's solution)
Study: 1298079
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg twice daily for two weeks
Study: 26560899
Drug: PEH-MR 30-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEH-MR 30-mg modified-release tablets every 12 hours for 7 days
Study: 26560899
Drug: PEH-MR 30-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEH-MR 30-mg modified-release tablets
Study: 22050410
Drug: Buspirone 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 20-mg
Study: 18562023
Drug: Coronary spasm
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary spasm group (sublingual nitroglycerin)
Study: 18562023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sublingual nitroglycerin)
Study: 16175767
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy (RSWT) - 2000 impulses, 4 weeks treatment
Study: 16175767
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - 20 impulses of RSWT, 4 weeks treatment
Study: 1989736
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 2 mg
Study: 1736698
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol 2 mg
Study: 6386593
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg intravenous infusion
Study: 27378545
Drug: Parent present
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent present during dental treatment
Study: 27378545
Drug: Parent absent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent absent during dental treatment
Study: 27378545
Drug: Children's perception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's perception of their treatment
Study: 22402934
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (SET) for PAD patients, duration of 3 weeks and 12 weeks, specific details on dosage not applicable.
Study: 16139699
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15 s after 60 s etching of enamel and 20 s etching of dentin
Study: 16139699
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15 s
Study: 16139699
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 30 s
Study: 16139699
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 45 s
Study: 16139699
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15, 30, and 45 s without pre-etching
Study: 7511106
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg t.i.d.)
Study: 12494049
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg o.d.)
Study: 12494049
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcium antagonists)
Study: 2323650
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and consolidation chemotherapy with weekly parenteral vincristine, Adriamycin, l-asparaginase and daily oral prednisone (VAAP), followed by standard CNS prophylaxis. Maintenance therapy for 3 years with daily 6-mercaptopurine, weekly methotrexate and monthly intrathecal therapy, with drug intensification comprising either vincristine, Adriamycin and l-asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP).
Study: 27217453
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) plus norethisterone
Study: 26711437
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml single use dropper bottle
Study: 26711437
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g single application squeeze tube containing gel
Study: 26711437
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml bottle with cotton swab
Study: 19040739
Drug: Ilioinguinal-iliohypogastric nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal-iliohypogastric nerve block (IINB) with 0.5% bupivacaine + 5 mcg/ml epinephrine (Group I, n = 28)
Study: 10847421
Drug: Enoxaparin (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.5, 1.0, and 2.0 mg/kg)
Study: 10847421
Drug: Dalteparin and
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin and Enoxaparin (therapeutic equivalent doses)
Study: 1825799
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (administered according to two schedules: early at birth, 3 months, and 6 months; later at 3 months, 4.5 months, and 6 months)
Study: 1825799
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (unscheduled administration)
Study: 11219162
Drug: Poliomyelitis vaccine
Normalized name: Poliomyelitis vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poliomyelitis vaccine
Study: 27418815
Drug: Glycopyrronium (GLY)
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (GLY) 50 μg
Study: 31096036
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 μg
Study: 18165405
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Vestibulectomy, Biofeedback, Cognitive-behavioral therapy)
Study: 8504436
Drug: Intravenous 4-aminopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 4-aminopyridine (4-AP)
Study: 8504436
Drug: Oral 4-aminopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 4-aminopyridine (4-AP) at maximum daily dosage of 0.5 mg/kg body weight, three times a day for 12 weeks
Study: 26420970
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 days)
Study: 26420970
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days)
Study: 21708034
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (MSM) 1.125 grams 3 times daily for 12 weeks
Study: 21708034
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily for 12 weeks
Study: 16817081
Drug: Ethacridine lactate
Normalized name: ethacridine lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethacridine lactate (10 ml per gestational week, max 200 ml)
Study: 16817081
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 microg intravaginally, followed by 100 microg oral every 4 hours for 24 hours)
Study: 16817081
Drug: Misoprostol +
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol + Oxytocin (administered similarly to group III)
Study: 31697817
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion threshold of 25 × 10^9/L
Study: 31697817
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion threshold of 50 × 10^9/L
Study: 21994233
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus methotrexate (5 mg/kg at weeks 0, 2, 6, and 14 plus 15 mg/week methotrexate)
Study: 21994233
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (15 mg/week)
Study: 15583700
Drug: sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine (10 mg/day)
Study: 12397571
Drug: Beta-agonist use
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonist use
Study: 10534551
Drug: iloprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month)
Study: 10534551
Drug: low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose oral cyclosporin A (2.5 mg/kg/day) associated with iloprost
Study: 2141289
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus dexamethasone 0.5 mg in the morning and 0.3 mg at night
Study: 2141289
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus cyproterone acetate 100 mg 3 times per day
Study: 484522
Drug: Pyridoxine 2
Normalized name: pyridoxine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 2 mg
Study: 484522
Drug: Pyridoxine 100
Normalized name: pyridoxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 100 mg
Study: 484522
Drug: Pyridoxine 100
Normalized name: pyridoxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 100 mg (retreatment)
Study: 31570495
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus (PIB) delivery of local anesthetic (10 mL of ropivacaine 0.2% every 2 hours)
Study: 31570495
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) (5 mL/hour) of local anesthetic
Study: 30373650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tongue scraping and aPDT with Bixa orellana extract
Study: 26488941
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) - transdermal
Study: 24500111
Drug: β-alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine (BA) supplementation (6.4 g day(‐1)) for 4 weeks
Study: 23151451
Drug: MuStDO5 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: MuStDO5 DNA vaccine with 500 μg of each plasmid and escalating doses of hGM-CSF (0, 20, 100 or 500 μg)
Study: 19570108
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of antipsychotics and mood stabilizers
Study: 17666974
Drug: Experimental breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental breast cancer treatment
Study: 15083253
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate
Study: 2517282
Drug: Adjuvant portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant portal infusion (5‐Fluorouracil 500 mg/m2/d x 7 continuous infusion + Mitomycin‐C 10 mg/m2 on day 1 as a bolus injection)
Study: 2517282
Drug: Full-dose adjuvant
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose adjuvant chemotherapy (among 195 patients, 85%)
Study: 2517282
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (overall)
Study: 1166982
Drug: Warfarin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (daily doses for 21 days)
Study: 1166982
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus rifampin (600 mg a day orally for the last 10 days)
Study: 31556537
Drug: Naloxone nasal
Normalized name: naloxone Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone nasal spray 2 mg (20 mg/ml)
Study: 22541841
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone 1 mg
Study: 22424843
Drug: Adalimumab (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (Group I, n=8) administered from post-operative day 14
Study: 22424843
Drug: Adalimumab (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (Group II, n=15) administered at 6 months post-operatively after confirmation of endoscopic recurrence despite treatment with azathioprine, infliximab, or 5-ASA
Study: 19416298
Drug: PCT-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided treatment in COPD subgroup
Study: 19416298
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in COPD subgroup
Study: 17206943
Drug: budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide 6 mg and ursodeoxycholic acid 15 mg/kg
Study: 1910019
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment placed on arm
Study: 1910019
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment placed on chest
Study: 6351663
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Mr 1268
Study: 1266667
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pentazocine
Study: 31974081
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase under current local resources
Study: 31974081
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase under assumed ideal conditions
Study: 31974081
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy plus intravenous alteplase under assumed ideal conditions
Study: 31974081
Drug: Interventional neuroradiologists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional neuroradiologists' decision to refrain from intravenous alteplase under assumed ideal conditions
Study: 25887932
Drug: Hydros (hyaluronan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution)
Study: 25887932
Drug: Hydros-TA (HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydros-TA (HA plus 10 mg of triamcinolone acetonide)
Study: 25887932
Drug: Synvisc-One (hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synvisc-One (hylan G-F 20)
Study: 24075893
Drug: γ-T-rich supplementation
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-T-rich supplementation (500 mg γ-T/day)
Study: 19619148
Drug: Botox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox (20 I.E. diluted in 0.5 mL saline)
Study: 19619148
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL saline)
Study: 7921346
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol infusion (0.5 g ethanol per kg body weight in 15 minutes)
Study: 2662037
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g elemental calcium for 5 days)
Study: 31960275
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (250 mg magnesium oxide) for 8 weeks
Study: 27995531
Drug: Subcutaneous IFN‐β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week (group 1)
Study: 27995531
Drug: Subcutaneous IFN‐β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 40 mcg and desogestrel 125 mcg (group 3)
Study: 27995531
Drug: Subcutaneous IFN‐β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (group 2)
Study: 25496007
Drug: Beclabuvir 75
Normalized name: Beclabuvir
DrugBank: Beclabuvir (DB12225)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Beclabuvir 75 mg plus pegIFN (180 μg) and RBV (1000 mg/day [<75 kg])
Study: 25496007
Drug: Beclabuvir 150
Normalized name: Beclabuvir
DrugBank: Beclabuvir (DB12225)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Beclabuvir 150 mg plus pegIFN (180 μg) and RBV (1200 mg/day [≥ 75 kg])
Study: 23979614
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (low dose regimen for a Bishop score equal to or more than 7)
Study: 20977367
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (7.5 mg total: 5 mg/0.2 mL on the day of surgery and 2.5 mg on the fourth day after surgery)
Study: 20977367
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (0.2 mL at the end of surgery)
Study: 19242918
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (n=38) for post-treatment survivors
Study: 810719
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (urgent surgical coronary bypass)
Study: 810719
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and Surgical therapy
Study: 31005973
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (20 g daily for 4 weeks)
Study: 28891830
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid infusion (5 mL/kg/h lactated Ringer solution)
Study: 28891830
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid infusion (30 mL/kg/h lactated Ringer solution)
Study: 25358078
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg of sublingual misoprostol
Study: 25358078
Drug: 25 mcg
Normalized name: D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mcg of vaginal misoprostol
Study: 21375093
Drug: Subinguinal technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subinguinal technique (5 ml of 1% mepivacaine)
Study: 21375093
Drug: Nerve-targeting technique
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve-targeting technique (5 ml of 1% mepivacaine)
Study: 19690428
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a dose of 0.066 mg/kg body weight per day
Study: 15278758
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first and second injections
Study: 15278758
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first injection and only 10 cc of 1% lignocaine for the second injection
Study: 15278758
Drug: only 10
Normalized name: SYRINGE,ORAL GRADUATED METRIC ONLY 10ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: only 10 cc of 1% lignocaine for the first and second injections
Study: 28190797
Drug: 60 min
Normalized name: TITANIUM DIOXIDE 6 g in 100 g / ZINC OXIDE 4.6 g in 100 g TOPICAL STICK [SPF 60 Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 min physical exercise (PE) at school daily
Study: 28190797
Drug: 2 units
Normalized name: Afrezza, 12 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 units of 45-min PE weekly (control group)
Study: 11232683
Drug: EUS-guided celiac
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided celiac plexus block with 10 cc bupivacaine (0.25%) and 3 cc (40 mg) triamcinolone injected on each side of the celiac plexus.